Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Cibolo Pediatric Dentistry and Orthodontics Dr. Lauren Digioia Cibolo Pediatric Dentistry & Orthodontics launches FOREVERSMILE, a re ...

Brain tumors remain the most common cause of death from childhood cancer. Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than ...

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...

Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

A new screening intervention in the primary care setting can improve the identification and management of obesity risk in pediatric patients, according to a poster presented at the National ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Brain tumours remain the most common cause of death from childhood cancer. Paediatric high-grade gliomas (pHGG) in particular ...

By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.